SUSVIMO
HCP & DTC
SUSVIMO is first-of-its-kind ocular implant that continuously delivers medication to treat wet age-related macular degeneration (AMD). Through its unique dosing system, SUSVIMO gives patients the option to go from monthly eye injections to as few as 2 per year. SUSVIMO launched in October 2021 and effectively relaunched in October 2022 with the Everywhere You Go (DTC) and Everywhere They Go (HCP) campaign to highlight its innovative delivery method and freedom from monthly injections.
Client: Genentech
Years: December, 2021–October, 2022
Creative Directors: Ed Stehlin, Ryan Goldberg
Copywriters: Steven Su, Matt Ingardia, Kelly Slonaker
Art Directors: Olivia Acerra, Madison Grube, Yunuén Sigler
Work done at FCBHealthNY (RIP 🥲)
Everywhere You Go featured across our website, Welcome Kit, Patient Consideration Brochure, and emails.
Patient Materials
Welcome Kit
Patient Consideration Brochure
Emails
For our retina specialists and ophthalmologists, we put greater focus on the innovative technology that makes SUSVIMO a first-in-class treatment. In our iVA and HCP website, clinical leave behind, campaign launch emails, banner ads, and Twitter posts, we distinguished SUSVIMO as a durable, long-acting treatment with proven clinical results for patients, Everywhere They Go.
HCP Materials
HCP Website
iVA
Journal Ad + Cover Tip
Banner Ads
Emails
Conventions & Conferences